Table 3.
Incidence of comorbidities on biologic therapy in the three registers
| UK JIA Biologics Registers | BiKeR | JuMBO | Pharmachild | |||||
|---|---|---|---|---|---|---|---|---|
| Total number of patients | 2185 | 1256 | 2475b | |||||
| ILAR | ||||||||
| Oligoarthritis | 579 (26%) | 298 (24%) | 834 (34%) | |||||
| (Persistent) | 181 (8%) | 47 (4%) | 430 (17%) | |||||
| (Extended) | 398 (18%) | 251 (20%) | 404 (16%) | |||||
| Polyarticular RF− | 715 (33%) | 345 (27%) | 699 (28%) | |||||
| Polyarticular RF+ | 189 (9%) | 125 (10%) | 106 (4%) | |||||
| Systemic | 226 (10%) | 84 (7%) | 291 (12%) | |||||
| Psoriatic | 133 (6%) | 93 (7%) | 95 (4%) | |||||
| Enthesitis | 212 (10%) | 266 (21) | 266 (11%) | |||||
| Undiff. | 64 (3%) | 45 (4%) | 184 (7%) | |||||
| Unknown | 67 (3%) | 0 (0%) | 0 (0%) | |||||
| Total biologic exposure, years | 6078 | 5180 | 1920 | 4778 | ||||
| Individual biologic exposurea, years | ||||||||
| TNF-α inhibitors | ||||||||
| Adalimumab | 1176 | 570 | 521 | 1332 | ||||
| Certolizumab | – | 4 | 94 | 7 | ||||
| Etanercept | 3193 | 4222 | 571 | 2260 | ||||
| Golimumab | 6 | 20 | 110 | 50 | ||||
| Infliximab | 686 | 56 | 154 | 125 | ||||
| IL-1 inhibitors | ||||||||
| Anakinra | 132 | 66 | 25 | 112 | ||||
| Canakinumab | 5 | 21 | 13 | 139 | ||||
| Other | ||||||||
| Abatacept | 167 | 95 | 62 | 348 | ||||
| Baricitinib | 3 | 1 | 10 | <1 | ||||
| Rituximab | 94 | 4 | 41 | 4 | ||||
| Secukinumab | – | 2 | 13 | – | ||||
| Tocilizumab | 794 | 120 | 306 | 400 | ||||
| Ustekinumab | 4 | – | – | – | ||||
| Frequency, N | Rate per 100 person years (95% CI) | Frequency, N | Rate per 100 person years (95% CI) | Frequency, N | Rate per 100 person years (95% CI) | Frequency, N | Rate per 100 person years (95% CI) | |
| Uveitis | 34 patients, N = 1781 | 0.7 (0.5, 1.0) | 10 patients, N = 1256 | 0.14 (0.07, 0.26) | 11 patients, N = 1256 | 0.33 (0.17, 0.60) | 7 patients, N = 1930 | 0.20 (0.08, 0.40) |
| MAS (systemic JIA only) | 4 patients N = 196 | 0.5 (0.2, 1.4) | 1 patient N = 82 | 0.15 (0.02, 1.13) | 1 patient N = 82 | 0.48 (0.07, 3.39) | 8 patients, N = 246 | 1.73 (0.75, 3.40) |
| Varicella | 96 patients, N = 2185 | 1.7 (1.4, 2.0) | 5 patients, N = 1256 | 0.07 (0.02, 0.16) | 1 patient, N = 1256 | 0.03 (0.001, 0.17) | 15 patients, N = 2475 | 0.32 (0.18, 0.53) |
| Herpes zoster | 46 patients, N = 2185 | 0.8 (0.6, 1.1) | 10 patients, N = 1256 | 0.14 (0.07, 0.26) | 6 patients, N = 1256 | 0.18 (0.07, 0.40) | 18 patients, N = 2475 | 0.38 (0.23, 0.61) |
| Varicella + herpes zoster | 139 patients, 55 (40%) hospitalized, N = 2185 | 2.5 (2.1, 2.9) | 15 patients, 2 (13%) hospitalized, N = 1256 | 0.21 (0.12, 0.35) | 7 patients, 1 (14%) hospitalized, N = 1256 | 0.21 (0.08, 0.44) | 33 patients, 3 (9%) hospitalized, N = 2475 | 0.70 (0.48, 0.99) |
| TB | 3 patients, N = 2185 | 0.05 (0.02, 0.15) | No patients, N = 1256 | – | 1 patient, N = 1256 | 0.03 (0.004, 0.22) | 5 patients, N = 2436 | 0.11 (0.03, 0.25) |
a
The sum of individual biologic exposures is greater than overall total exposure as it includes the 90 days added exposure window.
b
The number of Pharmachild patients ever treated with biologic therapy is greater than the number reported on biologic therapy at registration (Table 1).